ArticleProceedings of the National Academy of Sciences of the United States of America2016
Functions of vasopressin and oxytocin in bone mass regulation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 71 citations in OpenAlex.
- Bone turnover in arginine vasopressin deficiency: a comparative study with primary polydipsia and healthy controls.The Journal of clinical endocrinology and metabolism · 2026Trial
- Microbial lysate upregulates host oxytocin.Brain, behavior, and immunity · 2017Trial
- Hypothalamic prolactin receptorNature communications · 2026Article
- Neuroendocrine and neural control of bone mass in health and disease.The Journal of clinical investigation · 2026Review
- Neural regulation of bone: from central neural circuits to peripheral innervation of the skeletal stem cell niche.Bone research · 2026Review
- Sex-specific single transcript level atlas of vasopressin and its receptor (AVPR1a) in the mouse brain.eLife · 2026Article
- Article
- Advances in the regulation of bone metabolism by central nuclei: a new perspective on the brain-bone axis.Frontiers in neuroscience · 2026Review
- The Oxytocin System and Implications for Oxytocin Deficiency in Hypothalamic-Pituitary Disease.Endocrine reviews · 2025Review
- Neuroendocrinology of bone.Pituitary · 2024Review
- Connecting the dots: sex, depression, and musculoskeletal health.The Journal of clinical investigation · 2024Review
- Brain regulates weight bearing bone through PGE2 skeletal interoception: implication of ankle osteoarthritis and pain.Bone research · 2024Article
- Case report: Persistent syndrome of inappropriate antidiuresis after traumatic brain injury: spontaneous resolution and impact on RAAS and bone metabolism over five years.Frontiers in endocrinology · 2024Article
- The Effect of Oxytocin on Osteoporosis Improvement: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2024Review
- Pituitary crosstalk with bone, adipose tissue and brain.Nature reviews. Endocrinology · 2023Review
- Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management.Endocrine reviews · 2023Review
- Article
- Association of hyponatremia with bone mineral density and fractures: a narrative review.Therapeutic advances in endocrinology and metabolism · 2023Review
- Crosstalk within a brain-breast-bone axis regulates mineral and skeletal metabolism during lactation.Frontiers in physiology · 2023Review
- The mechanism of oxytocin and its receptors in regulating cells in bone metabolism.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 2 countries.
Funding
Abstract
Prior studies show that oxytocin (Oxt) and vasopressin (Avp) have opposing actions on the skeleton exerted through high-affinity G protein-coupled receptors. We explored whether Avp and Oxtr can share their receptors in the regulation of bone formation by osteoblasts. We show that the Avp receptor 1α (Avpr1α) and the Oxt receptor (Oxtr) have opposing effects on bone mass: Oxtr(-/-) mice have osteopenia, and Avpr1α(-/-) mice display a high bone mass phenotype. More notably, this high bone mass phenotype is reversed by the deletion of Oxtr in Oxtr(-/-):Avpr1α(-/-) double-mutant mice. However, although Oxtr is not indispensable for Avp action in inhibiting osteoblastogenesis and gene expression, Avp-stimulated gene expression is inhibited when the Oxtr is deleted in Avpr1α(-/-) cells. In contrast, Oxt does not interact with Avprs in vivo in a model of lactation-induced bone loss in which Oxt levels are high. Immunofluorescence microscopy of isolated nucleoplasts and Western blotting and MALDI-TOF of nuclear extracts show that Avp triggers Avpr1α localization to the nucleus. Finally, a specific Avpr2 inhibitor, tolvaptan, does not affect bone formation or bone mass, suggesting that Avpr2, which primarily functions in the kidney, does not have a significant role in bone remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.